The changing NHS environment means that payors are increasingly seeking value added offerings from pharmaceutical companies. Novartis is at the forefront of the products and services evolution in the pharmaceutical industry; recognising the need to develop a strong Business to Business (B2B) function within the strategy group focusing on value-added support services to deliver to patients the best possible care. B2B initiatives will prove to be of pivotal importance in payor decision making.